Gioacchino Chirico, president and CEO of Immucor, said: “We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions for blood transfusions to enhance patient outcomes.”
Gioacchino Chirico, president and CEO of Immucor, said: “We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions for blood transfusions to enhance patient outcomes.”